These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 32173694)

  • 1. NLR-A Simple Indicator of Inflammation for the Diagnosis of Left Ventricular Hypertrophy in Patients with Hypertension.
    Yu X; Xue Y; Bian B; Wu X; Wang Z; Huang J; Huang L; Sun Y
    Int Heart J; 2020 Mar; 61(2):373-379. PubMed ID: 32173694
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Atrial and brain natriuretic peptide and endothelin-1 concentration in patients with idiopathic arterial hypertension: the dependence on the selected morphological parameters.
    Irzmański R; Banach M; Piechota M; Kowalski J; Barylski M; Cierniewski C; Pawlicki L
    Clin Exp Hypertens; 2007 Apr; 29(3):149-64. PubMed ID: 17497342
    [TBL] [Abstract][Full Text] [Related]  

  • 3. B-type natriuretic peptide and left ventricular hypertrophy in hypertensive patients.
    Almeida P; Azevedo A; Rodrigues R; Dias P; Friões F; Vazquez B; Abreu-Lima C; Bettencourt P; Barros H
    Rev Port Cardiol; 2003 Mar; 22(3):327-36. PubMed ID: 12847875
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systemic immune-inflammation index (SII) may be an effective indicator in predicting the left ventricular hypertrophy for patients diagnosed with hypertension.
    Karayiğit O; Nurkoç SG; Çelik MC
    J Hum Hypertens; 2023 May; 37(5):379-385. PubMed ID: 36175554
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship between left ventricular geometry and natriuretic peptide levels in essential hypertension.
    Nishikimi T; Yoshihara F; Morimoto A; Ishikawa K; Ishimitsu T; Saito Y; Kangawa K; Matsuo H; Omae T; Matsuoka H
    Hypertension; 1996 Jul; 28(1):22-30. PubMed ID: 8675258
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Growth differentiation factor 15 can distinguish between hypertrophic cardiomyopathy and hypertensive hearts.
    Hanatani S; Izumiya Y; Takashio S; Kojima S; Yamamuro M; Araki S; Rokutanda T; Tsujita K; Yamamoto E; Tanaka T; Tayama S; Kaikita K; Hokimoto S; Sugiyama S; Ogawa H
    Heart Vessels; 2014 Mar; 29(2):231-7. PubMed ID: 23525862
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnostic potential of serum biomarkers for left ventricular abnormalities in chronic peritoneal dialysis patients.
    Wang AY; Lam CW; Wang M; Chan IH; Lui SF; Zhang Y; Sanderson JE
    Nephrol Dial Transplant; 2009 Jun; 24(6):1962-9. PubMed ID: 19237403
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Circulating natriuretic peptide concentrations in patients with end-stage renal disease: role of brain natriuretic peptide as a biomarker for ventricular remodeling.
    Cataliotti A; Malatino LS; Jougasaki M; Zoccali C; Castellino P; Giacone G; Bellanuova I; Tripepi R; Seminara G; Parlongo S; Stancanelli B; Bonanno G; Fatuzzo P; Rapisarda F; Belluardo P; Signorelli SS; Heublein DM; Lainchbury JG; Leskinen HK; Bailey KR; Redfield MM; Burnett JC
    Mayo Clin Proc; 2001 Nov; 76(11):1111-9. PubMed ID: 11702899
    [TBL] [Abstract][Full Text] [Related]  

  • 9. N-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide for identifying coronary artery disease and left ventricular hypertrophy in ambulatory chronic kidney disease patients.
    Khan IA; Fink J; Nass C; Chen H; Christenson R; deFilippi CR
    Am J Cardiol; 2006 May; 97(10):1530-4. PubMed ID: 16679099
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hypersensitive C-reactive protein as a potential indicator for predicting left ventricular hypertrophy in elderly community-dwelling patients with hypertension.
    Song W; Zhang C; Tang J; Li Y; Jiao T; Lin X; Wang Y; Fang J; Sha J; Ding T; Cheng J; Li J
    BMC Cardiovasc Disord; 2023 Sep; 23(1):480. PubMed ID: 37759159
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relation of left ventricular hypertrophy to microalbuminuria and C-reactive protein in children and adolescents with essential hypertension.
    Assadi F
    Pediatr Cardiol; 2008 May; 29(3):580-4. PubMed ID: 18046596
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnostic potential of cardiac natriuretic peptides in dialysis patients.
    Mallamaci F; Zoccali C; Tripepi G; Benedetto FA; Parlongo S; Cataliotti A; Cutrupi S; Giacone G; Bellanuova I; Stancanelli B; Malatino LS;
    Kidney Int; 2001 Apr; 59(4):1559-66. PubMed ID: 11260421
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Usefulness of B-type natriuretic peptide and C-reactive protein in predicting the presence or absence of left ventricular hypertrophy in patients with systemic hypertension.
    Conen D; Zeller A; Pfisterer M; Martina B
    Am J Cardiol; 2006 Jan; 97(2):249-52. PubMed ID: 16442372
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Brain natriuretic peptide as a marker of left ventricular hypertrophy in patients with aortic stenosis.
    Orlowska-Baranowska E; Baranowski R; Greszata L; Stepinska J
    J Heart Valve Dis; 2008 Nov; 17(6):598-605. PubMed ID: 19137789
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinical features and risk factors of left ventricular hypertrophy in children with primary hypertension].
    Liu Y; Shi L; Lin Y; Li YQ; Liu YY; Zhang HW
    Zhonghua Er Ke Za Zhi; 2023 Nov; 61(11):1031-1037. PubMed ID: 37899343
    [No Abstract]   [Full Text] [Related]  

  • 16. Plasma brain natriuretic peptide during ergometric exercise in hypertensive patients with left ventricular hypertrophy.
    Kohno M; Yasunari K; Yokokawa K; Horio T; Kano H; Minami M; Ikeda M; Yoshikawa J
    Metabolism; 1996 Nov; 45(11):1326-9. PubMed ID: 8931634
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exercise capacity and brain natruiretic peptide in hypertension.
    Lim PO; Donnan PT; Struthers AD; MacDonald TM
    J Cardiovasc Pharmacol; 2002 Oct; 40(4):519-27. PubMed ID: 12352313
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationships of Blood Pressure Circadian Rhythm and Brain Natriuretic Peptide with Left Ventricular Hypertrophy in the Patients with Primary Hypertension.
    Kou HJ; Wang X; Gao DF; Dong X; Wei J; Ma R
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2016 Oct; 38(5):514-521. PubMed ID: 27825406
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relation of left ventricular hypertrophy with systemic inflammation and endothelial damage in resistant hypertension.
    Salles GF; Fiszman R; Cardoso CR; Muxfeldt ES
    Hypertension; 2007 Oct; 50(4):723-8. PubMed ID: 17635853
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Brain natriuretic peptide as a marker for hypertensive left ventricular hypertrophy: changes during 1-year antihypertensive therapy with angiotensin-converting enzyme inhibitor.
    Kohno M; Horio T; Yokokawa K; Yasunari K; Ikeda M; Minami M; Kurihara N; Takeda T
    Am J Med; 1995 Mar; 98(3):257-65. PubMed ID: 7872342
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.